Randomized Withdrawal Study in Patients With Schizophrenia
Research payments
$323,990
Through program year 2025, $323,990 in research payments was reported against Randomized Withdrawal Study in Patients With Schizophrenia, across 23 payments, paid by Vanda Pharmaceuticals Inc..
- Paid by
- Vanda Pharmaceuticals Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $323,990 | 23 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Junaid Syed Saint Louis, MO Named on 3 payments
- Sherry Soefje Oceanside, CA Named on 3 payments
- Bethany Davis Atlanta, GA Named on 2 payments
- Robert Billingsley Fayetteville, AR Named on 2 payments
- Rishi Kakar Tamarac, FL Named on 1 payment
- Darrell Murray Atlanta, GA Named on 1 payment
- Charmaine Semeniuk San Diego, CA Named on 1 payment
- Jelena Kunovac Las Vegas, NV Named on 1 payment
- Aishwarya Prasad Bellevue, WA Named on 1 payment
- Peter Weiden Chicago, IL Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.